NEW YORK (GenomeWeb) – CareDx reported after the close of the market on Wednesday that its preliminary fourth quarter revenues grew between 61 percent and 65 percent, largely due to sales of Olerup HLA typing-branded products following the acquisition of Allenex AB in April 2016.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.